Santosh Kesari, Naveed Wagle, Jose A Carrillo, Akanksha Sharma, Minhdan Nguyen, Judy Truong, Jaya M Gill, Raffi Nersesian, Natsuko Nomura, Elnaz Rahbarlayegh, Garni Barkhoudarian, Walavan Sivakumar, Daniel F Kelly, Howard Krauss, Matias A Bustos, Dave S B Hoon, Lars Anker, Arun S Singh, Kamalesh K Sankhala, Tiffany M Juarez
PURPOSE: Chordomas are ultrarare tumors of the axial spine and skull-base without approved systemic therapy. Most chordomas have negative expression of thymidylate synthase (TS), suggesting a potential for responding to the antifolate agent pemetrexed, which inhibits TS and other enzymes involved in nucleotide biosynthesis. We evaluated the therapeutic activity and safety of high-dose pemetrexed in progressive chordoma. PATIENTS AND METHODS: Adult patients with previously treated, progressive chordoma participated in an open-label, single-institution, single-arm, pilot clinical trial of intravenous pemetrexed 900 mg/m2 every 3 weeks and supportive medications of folic acid, vitamin B12, and dexamethasone...
December 4, 2023: Clinical Cancer Research